Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

53.08
-1.8200-3.32%
Pre-market: 52.84-0.2400-0.45%05:12 EST
Volume:587.93K
Turnover:32.05M
Market Cap:1.47B
PE:-18.46
High:57.65
Open:54.62
Low:52.56
Close:54.90
52wk High:57.65
52wk Low:13.99
Shares:27.69M
Float Shares:14.25M
Volume Ratio:0.93
T/O Rate:4.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8757
EPS(LYR):-5.1170
ROE:-308.02%
ROA:-4.23%
PB:-49.96
PE(LYR):-10.37

Loading ...

Eric J. Loumeau, Chief Legal Officer, Reports Disposal of AnaptysBio Inc. Common Shares

Reuters
·
Feb 14

Is It Time To Reassess AnaptysBio (ANAB) After A 198% One-Year Share Price Surge

Simply Wall St.
·
Feb 06

AnaptysBio kündigt Abspaltung von Biopharma-Geschäft und Royalty-Vermögenswerten bis Ende 2026 an

Reuters
·
Feb 06

AnaptysBio Is Maintained at Overweight by Barclays

Dow Jones
·
Jan 21

Barclays Sticks to Their Buy Rating for AnaptysBio (ANAB)

TIPRANKS
·
Jan 20

U.S. RESEARCH ROUNDUP-Alphabet, Micron Technology, Microsoft

Reuters
·
Jan 20

AnaptysBio Director Magda Marquet Reports Disposal of Common Shares

Reuters
·
Jan 17

What AnaptysBio (ANAB)'s Royalty Spin-Off Plan Means For Shareholders

Simply Wall St.
·
Jan 10

AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties

Benzinga_recent_news
·
Jan 10

UK Stocks-Factors to watch on January 9

Reuters
·
Jan 09

BRIEF-Anaptys Files Motion To Dismiss Tesaro'S Claim Of Anticipatory Breach Of Contract In Ongoing Litigation

Reuters
·
Jan 09

AnaptysBio Seeks Dismissal of Tesaro’s Breach Claim in Delaware Court

Reuters
·
Jan 09

Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK Subsidiary

THOMSON REUTERS
·
Jan 09

AnaptysBio Inc - Trial in Anaptys and Tesaro/GSK Dispute Set for July 14-17, 2026

THOMSON REUTERS
·
Jan 09

AnaptysBio CFO Dennis Mulroy Reports Disposal of Common Shares

Reuters
·
Jan 09

UBS Upgrades AnaptysBio to Buy From Neutral, Adjusts Price Target to $70 From $20

MT Newswires Live
·
Jan 07

AnaptysBio to Split Biopharma Operations and Royalty Assets by 2026

Reuters
·
Jan 07

AnaptysBio CFO Dennis Mulroy Reports Sale of Common Shares

Reuters
·
Dec 24, 2025

AnaptysBio CFO Dennis Mulroy Reports Disposal of Common Shares

Reuters
·
Dec 19, 2025

AnaptysBio Is Maintained at Overweight by Barclays

Dow Jones
·
Dec 18, 2025